KYMR•benzinga•
Truist Securities Reiterates Buy on Kymera Therapeutics, Lowers Price Target to $53
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 1, 2024 by benzinga